Sugi Predict

Sugi Predict / Compounds / SCHEMBL9946168

SCHEMBL9946168

SCHEMBL9946168

CC1(C)OB(c2ccccc2OCc2ccccc2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ DGAT1 O75907 1/20 0.48
▸ LIPE Q05469 1/20 0.45
▸ HTR1A P08908 4/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ LTA4H P09960 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ BRD4 O60885 3/20 0.40
▸ ADRA1D P25100 3/20 0.40
▸ ADRA1A P35348 3/20 0.40
▸ ADRA1B P35368 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ LPL P06858 1/20 0.40
▸ LIPG Q9Y5X9 1/20 0.40
▸ ALPG P10696 1/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ ANPEP P15144 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463582 0.88 ABCB1 (0.46) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL16706964 0.88 DGAT1 (0.44) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL20819186 0.87 ABCB1 (0.49) DGAT1HTR1AADRA1DADRA1AADRA1B
SCHEMBL3299324 0.87 L3MBTL1 (0.46) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL2113350 0.86 L3MBTL1 (0.45) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL4659537 0.85 LMNA (0.46) MAPTL3MBTL1GAASGMS2
SCHEMBL19830896 0.84 DGAT1 (0.48) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL1753769 0.84 DGAT1 (0.44) MAPTMAPK1TDP1L3MBTL1DGAT1
SCHEMBL20805182 0.84 DGAT1 (0.52) DGAT1
SCHEMBL25819319 0.84 DGAT1 (0.44) MAPTMAPK1TDP1L3MBTL1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720076-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. Lundbeck A/S (DK) 2026-04-08 — — EP disclosed
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists H. LUNDBECK A/S (DK) 2026-03-31 — — US disclosed
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2025-08-21 — — US disclosed
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-26 — — US disclosed
WO-2024246285-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-05 — — WO disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 — — US disclosed
EP-2920183-B1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-03-08 — — EP disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 — — US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 — — US disclosed
EP-2920183-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS Glaxosmithkline LLC (US) 2015-09-23 — — EP disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 — — US disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 — — US disclosed
US-9012651-B2 TRPV3 modulators ABBVIE INC. (US) 2015-04-21 — — US disclosed
WO-2014078257-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-05-22 — — WO disclosed
US-20120245124-A1 TRPV3 Modulators ABBOTT LABORATORIES (US) 2012-09-27 — — US disclosed
WO-2012129491-A1 TRPV3 MODULATORS ABBOTT LABORATORIES (US) 2012-09-27 — — WO disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 MAPT 2718/4885MAPK1 2307/4885TDP1 3577/4885
US-20120245124-A1 TRPV3 Modulators TRPV3, TRPV2, TRPV1 MAPT 3335/4885MAPK1 2283/4885TDP1 3763/4885
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS BRD4, BET1, BRD3 MAPT 459/4885MAPK1 878/4885TDP1 618/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 MAPT 2718/4885MAPK1 2307/4885TDP1 3577/4885
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists HCRTR2, HCRTR1, OXER1 MAPT 4476/4885MAPK1 2083/4885TDP1 4396/4885
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 MAPT 3846/4885MAPK1 3305/4885TDP1 4870/4885
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR2 MAPT 3846/4885MAPK1 3305/4885TDP1 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.